Chung Iu
President chez Shanghai Mingyuan Enterprise Group Co. Ltd.
Profil
Chung Iu is currently the Vice Chairman & President at Shanghai Mingyuan Enterprise Group Co. Ltd.
and a Director at HD Global Ltd.
since 2003.
Previously, he worked as an Executive Director at Mingyuan Medicare Development Co. Ltd.
from 2010 to 2011.
Postes actifs de Chung Iu
| Sociétés | Poste | Début |
|---|---|---|
HD Global Ltd.
 HD Global Ltd. Pharmaceuticals: MajorHealth Technology Part of Mingyuan Medicare Development Co. Ltd., HD Global Ltd. is a Chinese company that researches, develops, and commercializes proteomic products. The company is based in Huzhou, China. HD Global was acquired by Mingyuan Medicare Development Co. Ltd. on July 16, 2003 for $9.81 million. | Directeur/Membre du Conseil | 19/03/2010 |
| Shanghai Mingyuan Enterprise Group Co. Ltd. | President | 19/03/2010 |
Anciens postes connus de Chung Iu
| Sociétés | Poste | Fin |
|---|---|---|
| MINGYUAN MEDICARE DEVELOPMENT CO., LTD. | Directeur/Membre du Conseil | 15/02/2011 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Mingyuan Medicare Development Co. Ltd.
 Mingyuan Medicare Development Co. Ltd. BiotechnologyHealth Technology Mingyuan Medicare Development Co. Ltd. engages in provision of medicare solutions for the early detection and prevention of diseases particularly in China. It operates through the following segments: Protein Chips, Healthcare, Medical Centers Management, Individualized Target Therapy, and Bio-Drugs. The Protein Chips segment manufactures and distributes C-12 products to hospitals, medical centers, and life insurance companies in China. The Healthcare segment engages in the provision of sales and marketing campaign for HPV DNA testing kits and making important progress to register products for distribution to female patients at hospitals nationwide. The Medical Centers Management segment engages in the provision of healthcare services for residents living in cities. The Individualized Target Therapy segment specializes in molecular diagnostic kits for leukemia, lymphoma and individualised target cancer therapy. The Bio-Drugs segment engages in the development, production and commercialization of a new generation of non-specific nanotechnology immunomodulatory drugs known as non-cell Corynebacterium pavum products. The company was founded on May 8, 1989 and is headquartered in Hong Kong. | Health Technology |
HD Global Ltd.
HD Global Ltd. Pharmaceuticals: MajorHealth Technology Part of Mingyuan Medicare Development Co. Ltd., HD Global Ltd. is a Chinese company that researches, develops, and commercializes proteomic products. The company is based in Huzhou, China. HD Global was acquired by Mingyuan Medicare Development Co. Ltd. on July 16, 2003 for $9.81 million. | Health Technology |
| Shanghai Mingyuan Enterprise Group Co. Ltd. |
